HUA MEDICINE (SHANGHAI) LTD. Funds and ETFs Hua Medicine (Shanghai) Ltd.
Equities
2552
KYG4644K1022
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.59 HKD | -3.05% |
|
-.--% | -19.29% |
| 03-28 | Hua Medicine Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 2023 | Hua Medicine Ltd. Appoints Yi Zhang as Executive Director with Effect from January 1, 2024 | CI |
ETFs positioned on Hua Medicine (Shanghai) Ltd.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.66% | 4 M€ | -27.92% | ||
| 0.00% | 117 M€ | -0.10% | - | |
| 0.00% | 4 M€ | -4.41% | - |
Hua Medicine is a China-based company principally engaged in the drug development business. The Company is mainly engaged in the development of an oral drug, Dorzagliatin, or HMS5552, for the treatment of Type 2 diabetes. The Company mainly operates its business in the domestic and overseas markets.
Calendar
26/06/2024
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.471
CNY
Average target price
2.892
CNY
Spread / Average Target
+96.54%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -19.29% | 199M | |
| -3.46% | 102B | |
| +1.41% | 96.09B | |
| +2.13% | 22.28B | |
| -15.84% | 21.4B | |
| -10.02% | 18.14B | |
| -39.98% | 17.02B | |
| -14.65% | 16.09B | |
| +4.39% | 13.83B | |
| +31.35% | 11.97B |
- Stock Market
- Equities
- 2552 Stock
- Funds and ETFs Hua Medicine (Shanghai) Ltd.
